Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

GT Biopharma (GTBP) Debt to Equity (2016 - 2021)

GT Biopharma (GTBP) has disclosed Debt to Equity for 12 consecutive years, with $0.01 as the latest value for Q3 2021.

  • On a quarterly basis, Debt to Equity rose 101.5% to $0.01 in Q3 2021 year-over-year; TTM through Sep 2021 was $0.01, a 101.5% increase, with the full-year FY2020 number at -$0.01, up 97.94% from a year prior.
  • Debt to Equity was $0.01 for Q3 2021 at GT Biopharma, down from $0.02 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $526.96 in Q3 2019 to a low of -$5.18 in Q1 2017.
  • A 5-year average of $28.94 and a median of $0.01 in 2021 define the central range for Debt to Equity.
  • Peak YoY movement for Debt to Equity: tumbled 9683.57% in 2017, then surged 653279.04% in 2018.
  • GT Biopharma's Debt to Equity stood at $0.0 in 2017, then skyrocketed by 1342373.77% to $0.8 in 2018, then crashed by 185.87% to -$0.69 in 2019, then skyrocketed by 97.94% to -$0.01 in 2020, then soared by 182.55% to $0.01 in 2021.
  • Per Business Quant, the three most recent readings for GTBP's Debt to Equity are $0.01 (Q3 2021), $0.02 (Q2 2021), and $0.02 (Q1 2021).